Unresolved Issues in the Treatment of Squamous Cell Carcinoma of the Esophagus. Brief Report

In recent years, chemotherapy for esophageal cancer has undergone significant changes. The emergence of new immunotherapeutic drugs has created new lines of therapy and significantly improved overall survival and progression-free survival rates in these patients. However, not all patients currently have access to modern treatments. Unfortunately, there is limited published data on the distribution of patients across different therapy options, as well as on treatment choices for patients in later lines of therapy. This article provides an overview of the available data on patient distribution across therapy lines and options.